Uncategorized
Phase 2 study initiated for oral anti-VEGF, anti-PDGF inhibitor
MIAMI — An oral tyrosine kinase inhibitor under study for use in treating wet age-related macular degeneration has moved forward into a phase 2 trial, a speaker said.Reporting positive phase 1 study results for X-82 (Xcovery Vision), an inhibitor of both anti-VEGF and anti-PDGF activity, Jason S. Slakter, MD, said at Angiogenesis, Exudation, and Degeneration 2015, “[X-82] has low toxicity in oral administration. Phase 1 study has shown some anatomic benefit, and a phase 2 program is kicking off.”